NEW YORK (Reuters) - Pfizer Inc. said on Monday the Federal Court of Appeal of Canada has blocked generic drugmaker Teva Pharmaceutical Industries Ltd. from launching a copycat form of its Celebrex ...

JERUSALEM (Legal Newsline) — Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic medications, announced Thursday that its U.S. subsidiary has entered into a settlement with ...

Strides Pharma Global, Singapore, has received approval for celecoxib capsules, 100 mg, 200 mg and 400 mg from the Food and Drug Administration. The product is the generic of Upjohn’s Celebrex. The ...

GAITHERSBURG, Md. — Pfizer Inc. should get American approval to market its Celebrex arthritis-pain pill for use in children because the benefits outweigh the risks, a Food and Drug Administration ...

Generic for celebrex 200 mg online american express Like other NSAIDs, including aspirin and ibuprofen, it works to reduce inflammation and pain associated with arthritis. This means celecoxib will ...

Pfizer will pay $94 million to resolve allegations that it used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex. The lawsuit, brought by 32 direct purchasers of ...

(Reuters) - U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on ...

A federal appeals court threw out one of three patents on Pfizer Inc.'s PFE wildly popular painkiller Celebrex, but backed a lowered court decision that ruled Teva Pharmaceutical Industries Ltd. TEVA ...

The US Food and Drug Administration (FDA) today approved the first generic versions of the anti-inflammatory drug celecoxib (Celebrex, Pfizer) in the wake of legal wrangling between the brand-name ...

The maker of the best-selling arthritis drug Celebrex will not be allowed to claim that its product is safer for the stomach and digestive tract than older, less expensive arthritis medicines, the ...

NEW YORK — Pfizer's surprise announcement of possible health risks connected with its Celebrex drug pushed stocks lower in heavy trading Friday, renewing investors' concerns over the pharmaceutical ...